There is currently a high demand for new therapeutic
antibiotics with new mechanisms of action. Disclosed are two small molecules, tryglysin A and B, with novel chemical structures and potent antibiotic activity against a
narrow spectrum of
bacteria. This
narrow spectrum of activity indicates the tryglysins could be working through a novel antibiotic
mechanism of action. Due to this
narrow spectrum, the tryglysins could be used as highly targeted therapeutics to treat or prevent
disease without disturbing other important, “beneficial”
bacteria within the human
microbiome, which is a great improvement over virtually all other clinically used
antibiotics that are broad-spectrum. The tryglysins are potent against several streptococcal pathogens, including
Streptococcus pneumonia, the leading cause of pneumonia, and
Streptococcus mutans, the primary causative agent of tooth decay and gum
disease. The tryglycins may allow the development of therapeutics for the treatment and / or prevention of
disease caused by these streptococci.